Advocacy
September 15, 2021, APNA signed on to a letter to the FDA expressing concerns about the new Clozapine REMS and its impact on patient care along with recommendations.
September 15, 2021, APNA signed on to a letter to the FDA expressing concerns about the new Clozapine REMS and its impact on patient care along with recommendations.
Connect with fellow psychiatric-mental health nurses, be the first to know about evidence-based resources and programs, and participate in exclusive opportunities to advance the care and treatment of those with mental health & substance use needs.
